# Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy

> **NCT05154474** · — · UNKNOWN · sponsor: **Weprom** · enrollment: 150 (estimated)

## Conditions studied

- Metastatic Cancer
- Cancer, Breast
- Cancer Colon
- Cancer, Rectum
- Cancer, Lung
- Cancer Ovaries
- Cancer Prostate
- Cancer, Kidney
- Cancer Pancreas
- Myeloma
- Myelodysplasia
- Leukemia, Myeloid, Acute
- Leukemia,Myeloid, Chronic
- Leukemia, Lymphocytic, Acute
- Leukemia, Lymphocytic, Chronic

## Interventions

- **OTHER:** Standard

## Key facts

- **NCT ID:** NCT05154474
- **Lead sponsor:** Weprom
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06
- **Primary completion:** 2023-02
- **Final completion:** 2024-08
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2022-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05154474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05154474, "Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05154474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*